Andrew T. Cheng

Andrew T. Cheng's work experience includes:

- Senior Staff Scientist at Pendulum Therapeutics from January 2022, with previous roles as a Staff Scientist from November 2019 to January 2022, Senior Scientist from October 2016 to November 2019, and Scientist II from October 2015 to October 2016.

- Principal Microbiologist at Flora Therapeutics Inc from July 2015 to October 2015.

- Ph.D. Candidate at the University of California, Santa Cruz from September 2009 to June 2015, where they conducted research on two-component signal transduction systems in Vibrio cholerae and established a workflow assay for transcriptome profiling.

- Senior Research Associate at Osel Inc from October 2006 to September 2009, where they worked on the development of a topical live biotherapeutic to prevent HIV transmission and evaluated bacterial colonization in nonhuman primate models.

- Research Associate at Epitomics - an Abcam Company in July 2006.

- Research Intern at the University of California, Davis, Department of Pathology, Microbiology, and Immunology from January 2004 to June 2006.

Andrew T. Cheng completed their Bachelor's Degree in Biotechnology with an emphasis in Microbiology/Fermentation from the University of California Davis from 2001 to 2006. Andrew T. went on to pursue a Doctor of Philosophy (Ph.D.) in Microbiology and Environmental Toxicology at the University of California, Santa Cruz from 2009 to 2015.